And offers relief to sleepy Quebecers
MONTREAL, Feb. 20, 2013 /CNW Telbec/ - VitalAire, whose clinicians have been treating patients for obstructive
sleep apnea (OSA) for the past 30 years, announces the launch of the
state-of-the-art Sleep Testing Laboratory, the first for VitalAire in Canada. OSA, a serious condition, is said
to affect up to 20% of adult Canadians.
Today, 75% of OSA patients in Canada remain undiagnosed. With this new
sleep testing laboratory, patients can now receive a prescribed overnight sleep study without having to wait. The VitalAire Sleep Laboratory is overseen by
Medical Director Dr. Sean A. Gilman, board-certified in sleep medicine,
as well as a team of VitalAire clinicians. The new Sleep Testing
Laboratory is located at the Best Western (Suite 104, Mezzanine level)
on Drummond Street in downtown Montreal.
With Dr. Gilman, VitalAire provides patients with a full range of
diagnostic services to ensure that they receive evaluation, diagnosis
and appropriate treatment in a quick and seamless manner. The referring
GP generally conducts the follow-up.
"We are proud to now offer supervised overnight sleep testing services
for our patients and referring physicians in Quebec. At the same time,
we have expanded our in-home sleep testing services to cover our entire
network of VitalAire Quebec sleep clinics, with the option of
supervised overnight tests," said Cecile Perraud, Regional Director for VitalAire Quebec.
In Quebec, VitalAire operates the cutting-edge Sleep Laboratory, along
with 11 sleep clinics across the province, in Montreal East and Downtown, the West Island,
Longueuil, Saint-Jerôme, Joliette, Saint-Hyacinthe, Quebec City,
Valleyfield and Gatineau, as well as Sorel, which opened in the fall of
Part of the Air Liquide Group, VitalAire is a national health care
provider with more than 100 locations across Canada. Focusing
exclusively on respiratory services such as home oxygen, obstructive
sleep apnea and ventilation therapies, VitalAire has been helping
Canadians breathe easier for more than 40 years.
Air Liquide, European leader and 3rd worldwide in home healthcare, provides home healthcare services in compliance with medical
prescription for patients suffering from chronic illnesses such as COPD (Chronic Obstructive Pulmonary Disease), sleep apnea and
diabetes. These home healthcare services are being developed in
addition to hospital care, enabling patients to enjoy better quality of life and local authorities to reduce costs.
Home Healthcare represents 45% of Air Liquide's total 2011 Healthcare revenue.
Air Liquide is the world leader in gases for industry, health and the
environment, and is present in 80 countries with close to 50,000 employees. Oxygen, nitrogen, hydrogen and rare gases have been at the core of Air
Liquide's activities since its creation in 1902. Using these molecules,
Air Liquide continuously reinvents its business, anticipating the needs
of current and future markets. The Group innovates for the good of society while delivering growth and
Innovative technologies that curb polluting emissions, lower industry's energy use, recover and
reuse natural resources or develop the energies of tomorrow, such as
hydrogen, biofuels or photovoltaic energy… Oxygen for hospitals, home
healthcare, fighting nosocomial infections… Air Liquide combines many
products and technologies to develop valuable applications and services
not only for its customers but also for society.
A partner for the long term, Air Liquide relies on employee commitment, customer trust and
shareholder support to pursue its vision of sustainable, competitive
growth. The diversity of Air Liquide's teams, businesses, markets and geographic presence
provides a solid and sustainable base for its development and
strengthens its ability to push back its own limits, conquer new
territories and build its future.
Air Liquide explores the best that air can offer to preserve life,
staying true to its Corporate Social Responsibility and sustainable
development approach. In 2012, the Group's revenues amounted to € 15.3 billion of which 82% were generated outside France. Air Liquide is listed on
the Paris Euronext stock exchange (compartment A) and is a member of
the CAC 40 and Dow Jones Euro Stoxx 50 indexes
For further information: